Diagnostic Utility of p16 and MTAP Immunohistochemistry for Cellular Neurothekeomas
Journal of Cutaneous Pathology · 05.11.2026
DOI: 10.1111/cup.70243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 05.11.2026. Verfasst von Joseph S Durgin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Wellcome Trust, UKRI DERMATLAS Project.
Abstract (Originalsprache)
Aims
Cellular neurothekeoma (cNTK) is a benign cutaneous tumor of uncertain histogenesis. Recent genomic characterization identified recurrent deletions on chromosome 9p21.3, encompassing CDKN2A (p16), as a primary driver event in cNTK. We assessed the potential utility of p16 and MTAP immunohistochemistry for discriminating cNTKs from morphologic mimics. Methods and Results Immunohistochemistry for p16 and MTAP was performed on 21 and 19 cNTKs, respectively, and a broad comparison group of fibrohistiocytic neoplasms. Staining distribution was scored semi‐quantitatively. Low/absent p16 expression (Score 1) was observed in 17 of 21 (81%) cNTK cases. Low/absent p16 was significantly more likely in cNTK relative to atypical fibrous histiocytoma, dermatofibroma, Langerhans cell histiocytosis, and pleomorphic dermal sarcoma. However, there was no statistical difference relative to some other tumor types, including plexiform fibrohistiocytic tumor or atypical fibroxanthoma. Only 26% of assessed cNTK cases (5/19) showed loss of MTAP; this did not reach statistical significance relative to other tumor types.
Conclusions
Low/absent p16 expression is common in cNTKs, corroborating recent genetic evidence for 9p21.3 deletion. Diagnostic utility of low/absent p16 varied, with high specificity in comparison to atypical fibrous histiocytoma and low utility for plexiform fibrohistiocytic tumor. Despite its proximity to CDKN2A on 9p21.3, MTAP immunohistochemistry shows low sensitivity for cNTKs, with diminished staining in only a small subset of tumors. Our findings suggest that low/absent p16 can be diagnostically informative for cNTK in certain contexts; however, low specificity against some tumor types is an important limitation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
ORCID-Profile: Joseph S Durgin, Katharina Wiedemeyer, Scott C Bresler, Steven M Hrycaj, Louise van der Weyden, David J Adams, Paul W Harms
Förderung
- NIH HHS
- Wellcome Trust
- UKRI DERMATLAS Project
- National Institutes of Health
- UK Research and Innovation
Zitieren
APA
Durgin, J. S., Wiedemeyer, K., Wang, G., Bresler, S. C., Hrycaj, S. M., van der Weyden, L., Adams, D. J., Brenn, T., & Harms, P. W. (2026). Diagnostic Utility of p16 and MTAP Immunohistochemistry for Cellular Neurothekeomas. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70243
Vancouver
Durgin JS, Wiedemeyer K, Wang G, Bresler SC, Hrycaj SM, van der Weyden L, et al. Diagnostic Utility of p16 and MTAP Immunohistochemistry for Cellular Neurothekeomas. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.70243
BibTeX
@article{Durgin2026,
author = {Durgin, Joseph S and Wiedemeyer, Katharina and Wang, Grace and Bresler, Scott C and Hrycaj, Steven M and van der Weyden, Louise and Adams, David J and Brenn, Thomas and Harms, Paul W},
title = {Diagnostic Utility of p16 and MTAP Immunohistochemistry for Cellular Neurothekeomas},
journal = {Journal of Cutaneous Pathology},
year = {2026},
doi = {10.1111/cup.70243}
}
EUVIMED